Revenue Breakdown
Composition ()
No data
Revenue Streams
CervoMed Inc (CRVO) generates its revenue primarily from ProElite, which accounts for 100.0% of total sales, equivalent to $72.00K. Understanding this concentration is critical for investors evaluating how CRVO navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, CervoMed Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2493.79%, while the net margin is -2395.34%. These profitability ratios, combined with a Return on Equity (ROE) of -71.42%, provide a clear picture of how effectively CRVO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CRVO competes directly with industry leaders such as WFCF and CIGL. With a market capitalization of $47.34M, it holds a significant position in the sector. When comparing efficiency, CRVO's gross margin of 100.00% stands against WFCF's 38.29% and CIGL's 31.80%. Such benchmarking helps identify whether CervoMed Inc is trading at a premium or discount relative to its financial performance.
